London, UK and Paris, France: 11 September 2006 - Antisoma today announces the presentation of new data on its antibody drug AS1402. These highlight the key role of white blood cells called natural killer (NK) cells in the action of the drug, which is currently being prepared for phase II trials in breast cancer.